Xenon Announces XEN1101 Pharmacodynamic Data From Phase 1b TMS Study For Treatment Of Epilepsy; XEN1101 Demonstrated Statistically Significant Reduction In Corticospinal And Cortical Excitability
Benzinga Newsdesk